Enter your keyword

A SKILLED AND HIGHLY EXPERIENCED TEAM, COMMITTED TO SUCCESS

Scientific Steering Committee

The following ovarian cancer experts are advising Mateon Therapeutics on our ongoing FOCUS Study which is evaluating PCC +bevacizumab +/- CA4P in platinum-resistant ovarian cancer (NCT02641639)

Committee Members:

Arizona Oncology (US Oncology Network) - Phoenix, AZ

Dr Monk is part of Arizona Oncology (US Oncology Network), Phoenix, AZ. He is also Professor, Gynecologic Oncology: University of Arizona and Creighton University, Phoenix, AZ . Dr. Monk’s expertise involves the multidisciplinary prevention and treatment (surgery, radiation and chemotherapy) of vulvar, vaginal, cervical, uterine, fallopian tube, primary peritoneal and ovarian cancers. He is a world-renowned leader in developing new therapeutic approaches and has published over 200 peer review manuscripts along with 30 book chapters dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and with patient quality of life.

Dr Monk is a fellow of the American College of Surgeons (ACS), the American College of Obstetricians and Gynecologists (ACOG), and the American Society for Colposcopy and Cervical Pathology (ASCCP), and is an active member of the Society of Gynecologic Oncology (SGO), American Society of Clinical Oncology (ASCO), and other professional organizations.

Dr Monk earned his medical degree at the University of Arizona College of Medicine and completed a residency in obstetrics and gynecology at the University of California, Los Angeles and his Gynecologic Oncology fellowship at University of California, Irvine.

Memorial Sloan Kettering Cancer Center – New York, New York

Dr Aghajanian is the Chief of Gynecologic Medical Oncology Service at Memorial Sloan Kettering Cancer Center in the Solid Tumor Division and attending physician in the Gynecologic Medical Oncology Service. She currently serves as an investigator on a number of Phase 2 and Phase 3 trials in gynecologic cancers. As a medical oncologist she focuses exclusively on the medical treatment of gynecologic cancers. She leads Memorial Sloan Kettering Cancer Center’s research program in chemotherapy for patients newly diagnosed with ovarian cancer and is an expert in the management of both advanced gestational trophoblastic disease and germ cell tumors of the ovary.

Dr Aghajanian is the co-principal investigator for Memorial Sloan Kettering participation in the Gynecologic Oncology Group (GOG) and serves on the Phase 1 committee and the Medical Oncology Committee for the GOG. Her recent honors include a career development award from the American Society of Clinical Oncology and the Boyer Award for outstanding young investigators at Memorial Sloan Kettering Cancer Center. New York Magazine awarded her Top Doctors in 2015 and 2016.

Dr Aghajanian received her medical degree from State University of New York (SUNY) Downstate Medical Center at Brooklyn. She completed a residency at Mount Sinai Medical Center (New York), and a fellowship at Memorial Sloan Kettering Cancer Center. She is board certified in internal medicine and medical oncology.

University of Alabama at Birmingham - Birmingham, Alabama

Dr Alvarez is Professor and Chair of the Department of Obstetrics and Gynecology at Vanderbilt University Medical Center. Previously he was Professor and Ellen Gregg Shook Culverhouse Chair of the Division of Gynecologic Oncology at the University of Alabama at Birmingham (UAB), serving as Director from 2003 to 2014. His long-term research interests have included the development of novel therapeutics for ovarian cancer and new screening and prevention strategies for cervical cancer.

He has been the recipient of several National Cancer Institute (NCI) and other industry-funded grants in support of his research in gene therapeutics for ovarian cancer and he is currently a co-principal investigator in cervical neoplasm vaccine projects included in the Johns Hopkins/UAB Cervical SPORE. He is currently co-chair of the NRG Oncology Gynecologic Committee and Principal Investigator of the UAB NCTN LAPS. He has served on study sections for the NCI Clinical Oncology Section and the Department of Defense’s Ovarian Cancer Research Program. Dr Alvarez has published over 250 articles in various peer-reviewed journals and has served on the editorial board of Gynecologic Oncology. In 2013 he served as President of the Society of Gynecologic Oncology. He is currently Director of Gynecologic Oncology Division of the American Board of Obstetrics and Gynecology.

Dr Alvarez has an MBA from Auburn University. He received his medical degree from Louisiana State University Medical Center and completed a residency in obstetrics and gynecology and fellowship in gynecologic oncology at UAB.

Arizona Oncology & US Oncology Research - Tucson, Arizona

Dr Bookman is the Medical Director of the Gynecologic Oncology Research Program for US Oncology Research and a medical gynecologic oncologist with Arizona Oncology, a practice in the US Oncology Network. He has extensive experience working for the National Cancer Institute, the Gynecologic Oncology Group (GOG), and the National Comprehensive Cancer Network, in the area of gynecologic cancers.

For more than 20 years, he has worked closely with the GOG to support clinical research for women with gynecologic cancers, and mentorship for junior investigators. His roles have included Chair of the Developmental Therapeutics Committee and the Committee on Information Technology. He has served as Chair of the Ovarian Committee since August 2010, during the transition to NRG Oncology as part of the NCI National Clinical Trials Network. In July 2006, Dr Bookman was appointed Director, Office of Educational Resources of the International Gynecologic Cancer Society (IGCS), continuing through 2016. This offered a unique opportunity to focus on the development of resources to support global and regional educational initiatives of the IGCS, targeting healthcare providers and patients in diverse international settings.

Dr Bookman received his medical degree from Harvard Medical School and completed a fellowship in medical oncology at the National Cancer Institute.

Sutter Health - San Francisco, California

Dr Chan is the Regional Cancer Center Director of Gynecologic Oncology at the California Pacific-Palo Alto Medical Foundation Research Institute. He also serves as the Principal Investigator Lead of Sutter Cancer Research Consortium. He holds the Denise & Prentis Cobb Hale Endowed Chair at the California Pacific Medical Center. He is an adjunct clinical professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Francisco, Stanford University and Dartmouth School of Medicine. His research focuses on developing new therapies for gynecologic cancers, including targeted biologic therapies, as well as investigating the role of immunotherapy in ovarian cancer. He also conducts outcomes-based and cost-effective studies evaluating the treatment of ovarian and uterine cancer.

Dr Chan serves on the Ovarian Committee of the Gynecologic Oncology Group and is the study chair of three Gynecologic Oncology Group protocols. He has received numerous grants and awards and has authored and co-authored more than 120 manuscripts.

Dr Chan received his medical degree from University of California, Los Angeles School of Medicine, completed his residency at University of California, Irvine and two fellowships one from MD Anderson Cancer Center and University of California, Irvine.

Arizona Oncology (US Oncology Network) - Phoenix, AZ

Dr. Chase is a part of Arizona Oncology (US Oncology Network), Phoenix, AZ. Her expertise includes research and collaborative projects with colleagues on scientific questions related to quality of life, symptom management, and supportive care.

Dr Chase is a member of NRG Oncology and a member of the group’s Health Outcomes Research Committee, a fellow of the American Congress of Obstetricians and Gynecologists, as well as an active member of the Society of Gynecologic Oncology and American Society of Clinical Oncology. She is a current member of the editorial board for the Journal of Palliative Care & Medicine and a reviewer for Gynecologic Oncology and the American Journal of Obstetrics and Gynecology. She has authored more than 30 peer-reviewed articles along with over 35 abstracts.

Dr Chase earned her medical degree at the University of California, Irvine where she also completed her residency and fellowship in gynecologic oncology.

University of Cincinnati Cancer Institute - Cincinnati, Ohio

Dr Herzog is the Clinical Director at the University of Cincinnati Cancer Institute and Professor of Obstetrics and Gynecology at the University of Cincinnati College of Medicine. He is currently Principal Investigator in a number of clinical trials with a special emphasis in ovarian and endometrial cancers.

Dr Herzog is a National Institutes of Health and an American Cancer Society–funded researcher and has published more than 200 peer-reviewed manuscripts. He has served as an active member of several professional societies including the American College of Surgeons, for which he is also on the elected board of governors, the American Board of Obstetrics and Gynecology, and the American Society for Colposcopy and Cervical Pathology. Dr Herzog is also Editor-in-Chief of Gynecologic Oncology Research and Practice and serves on the editorial boards for a number of other peer-reviewed journals.

Dr Herzog received his medical degree from the University of Cincinnati College of Medicine and completed his fellowship in gynecologic oncology at the Washington University School of Medicine.

Division of Gynecologic Oncology at the University of California, Irvine – Irvine, California

Dr Tewari is Professor and Director of Research in the Division of Gynecologic Oncology at the University of California, Irvine. He serves as the Principal Investigator of the National Cancer Institute’s NRG-Oncology Cooperative Group and Gynecologic Oncology Group Partners at the University of California, Irvine. At UC Irvine, Dr Tewari is the Director of the Women’s Disease Oriented Team for the Chao Family National Cancer Institute Designated Comprehensive Cancer Center. He is also the Director of the Gynecologic Oncology Program at St Joseph’s Center for Cancer Prevention and Treatment. Dr. Tewari is a voting member of the NRG’s Cervix Committee, Publications Committee, and Committee on Experimental Medicine, and Chairs the Society of Gynecologic Oncology’s (SGO) Publications Committee. In January 2016, Dr. Tewari was appointed Member-At-Large to the SGO’s Nominating Committee. Specializing in ovarian, endometrial, cervical, and other gynecologic cancers, he is highly trained in minimally invasive robotic-assisted surgery and helped establish the program at Long Beach Memorial.

In practice for more than 20 years, Dr Tewari continues to dedicate his career to the early diagnosis and treatment of gynecologic cancers. Dr. Tewari has published over 130 peer reviewed articles and written numerous book chapters. His research interests include novel targeted therapeutics in ovarian cancer and cervical cancer. Dr. Tewari has been listed for nine consecutive years as one of the Top Doctors in Orange County and has been listed in Best Doctors of America for the past 5 years.

Dr Tewari graduated from the University of California, Irvine School of Medicine, where he also completed his residency in Ob/Gyn, and fellowship in Gynecologic Oncology. He is board certified in gynecological oncology and obstetrics & gynecology.

Leuven Cancer Institute – Leuven, Belgium

Professor Vergote is Chairman of the Leuven Cancer Institute and Head of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic University of Leuven, Belgium. His clinical and translational research focuses on ovarian and uterine cancer. Professor Vergote was the first trained gynaecological oncologist in Belgium. He has authored more than 635 original full papers in peer-reviewed journals, together with 50 book chapters, and edited several books on gynaecological oncology. He is Editor of the European Journal of Cancer, and past-Associate Editor of Gynecologic Oncology and the International Journal of Gynaecological Cancer.

Professor Vergote is currently Chairman of the Belgian & Luxemburg Gynaecological Oncology Group (BGOG); Chairman of the protocol committee of European Organization for Research, and Treatment of Cancer – Gynecologic Cancer Group (EORTC-GCG); and President of the Society of Robotic European Gynaecological Surgery (SERGS). Professor Vergote was the founder and first chairman of European Network of Gynaecological Oncological Trial groups (ENGOT), and was also chairman and now a member of the board of the University Hospital Leuven. He has been chairman or president of several European gynaecological oncology associations. He has received prizes for his expertise in Austria and the Netherlands and been awarded honorary memberships in Finnish and American organizations.

Professor Vergote received his medical degree at the University of Ghent, Belgium, then trained in obstetrics and gynaecology at the University of Antwerp, Belgium. He specialized in gynaecologic oncology in the Department of Gynaecologic Oncology at the Norwegian Radium Hospital, where he later became staff member and then deputy chairman.